CGRP can bind to both the canonical CGRP receptor and the non-canonical CGRP receptor (AMY1); thus, an intriguing question is whether the CGRP receptor alone is the essential molecular site for anti-migraine therapy, or whether the AMY1 receptor is also involved in migraine pathophysiology, with amylin and/or CGRP being the primary ligand agonists [78]. Here, IAPP is linked to migraine disorder.